<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Coherus BioSciences, Inc.

    Coherus BioSciences, Inc.

    Coherus BioSciences is a leading biosimilar company that develops and commercializ...

    Coherus BioSciences is a leading biosimilar com...

    Filing Type:    PU
    Nuvectra Corporation

    Nuvectra Corporation

    NuvectraÂŽ is a neurostimulation company committed to helping physicians improve t...

    NuvectraÂŽ is a neurostimulation company commit...

    Filing Type:    PU
    Momenta Pharmaceuticals, Inc.

    Momenta Pharmaceuticals, Inc.

    Momenta Pharmaceuticals is a biotechnology company specializing in the detailed st...

    Momenta Pharmaceuticals is a biotechnology comp...

    Filing Type:    PU
    Halo Cures, Inc.

    Halo Cures, Inc.

    Halo gives scientists and academics opportunities to connect with industry partner...

    Halo gives scientists and academics opportuniti...

    Filing Type:    CF
    CAVU Biotherapies, Inc.

    CAVU Biotherapies, Inc.

    CAVU Biotherapies offers a comprehensive solution to prepare for, monitor, and tre...

    CAVU Biotherapies offers a comprehensive soluti...

    Filing Type:    CF
    electroCore, Inc.

    electroCore, Inc.

    electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated t...

    electroCore, Inc. is a commercial stage bioelec...

    Filing Type:    PU
    Cue Biopharma, Inc.

    Cue Biopharma, Inc.

    Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...

    Cue Biopharma is an innovative clinical stage i...

    Filing Type:    PU
    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...

    Phio Pharmaceuticals is focused on developing t...

    Filing Type:    PU
    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...

    Trillium Therapeutics Inc. is a clinical stage ...

    Filing Type:    PU
    Aduro Biotech, Inc.

    Aduro Biotech, Inc.

    Aduro is dedicated to its mission to discover, develop, and commercialize immunoth...

    Aduro is dedicated to its mission to discover, ...

    Filing Type:    PU
    IDEAYA Biosciences, Inc.

    IDEAYA Biosciences, Inc.

    IDEAYA is an oncology-focused precision medicine company committed to the discover...

    IDEAYA is an oncology-focused precision medicin...

    Filing Type:    PU
    Principia Biopharma Inc.

    Principia Biopharma Inc.

    We are a late-stage biopharmaceutical company dedicated to bringing transformative...

    We are a late-stage biopharmaceutical company d...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.